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Abstract: Viruses are the most common cause of acute respiratory tract infections (ARTI). Human
metapneumovirus (hMPV) frequently causes viral pneumonia which can become life-threatening if
the virus spreads to the lungs. Even though hMPV was only isolated in 2001, this negative-stranded
RNA virus has probably been circulating in the human population for many decades. Interestingly,
almost all adults have serologic evidence of hMPV infection. A well-established host immune
response is evoked when hMPV infection occurs. However, the virus has evolved to circumvent
and even exploit the host immune response. Further, infection with hMPV induces a weak memory
response, and re-infections during life are common. In this review, we provide a comprehensive
overview of the different cell types involved in the immune response in order to better understand
the immunopathology induced by hMPV. Such knowledge may contribute to the development of
vaccines and therapeutics directed against hMPV.
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1. Introduction
Acute respiratory tract infections (ARTI) are the most common cause of symptomatic illness
worldwide. Although some bacteria and fungi can cause ARTI, viruses are by far the most common
cause of ARTI [1,2]. ARTI that are confined to the upper respiratory tract typically result in mild
respiratory symptoms. However, when the infection spreads to the lungs, this can lead to life-threatening
pneumonia. Two members of the Pneumoviridae family, namely, human respiratory syncytial virus
(hRSV) and human metapneumovirus (hMPV), frequently cause viral pneumonia in infants and children
(<five years of age), the elderly (>65 years of age), and immune-compromised individuals [3–5]. hRSV,
first isolated in 1956 from a colony of chimpanzees [6], is now estimated to be the most common cause of
childhood pneumonia worldwide [7]. hMPV, first isolated from children in the Netherlands [3], is an
important cause of bronchiolitis and pneumonia in children[8–11]. Several studies have shown that up
to 95% of children infected with hMPV were previously healthy, indicating that young age is one of
the major factors influencing disease severity [12,13]. Hospitalization rates due to hMPV infection are
highest in the first five years, with a peak age between six and 12 months of age [12,14–19]. Interestingly,
a significant fraction of ARTI that was first considered to have an unknown cause is now attributed
to infection with hMPV, supporting early observations that hMPV had been circulating in the human
population long before it was first isolated [3]. Supporting that, nearly 100% of people test positive
for antibody reactivity in their blood by the age of 10, and almost all adults have serologic evidence of
prior hMPV infection [3,20–22]. hMPV is classified into two major genetic lineages, hMPV A and B, that
are further subdivided into lineages A1, A2, B1, and B2 [3,23,24]. The circulation of the four genetic
lineages of hMPV was confirmed in worldwide studies. Long-term retrospective studies conducted in
the United States from 1981 to 2001 concluded that multiple lineages can circulate in the same period at a
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given location [25,26]. Co-circulation of both hMPV A and B genotypes has been documented both in
children [27] and adults [28]. However, generally one lineage dominates a season, which varies year
by year [29,30]. Studies in rodents and non-human primates show a high degree of cross-protection
and -neutralization between different hMPV lineages [31]. However, studies using lineage-specific
antisera of ferrets and Syrian golden hamsters have shown that homologous virus-neutralizing titers were
significantly higher than titers against heterologous hMPV lineages and that the antigenic relatedness
between viruses from two genetic lineages was relatively low [32,33]. These observations of limited
cross-protection, together with reports of re-infections of macaques [34] and humans [35] with genetically
distinct hMPV strains, might explain why it is possible that multiple lineages of hMPV can co-circulate.
hMPV is an enveloped negative-stranded RNA virus with a non-segmented genome of
approximately13.3 kilobases. The viral genome comprises eight genes and codes for nine proteins:
nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), matrix-2 proteins (M2-1
and M2-2), small hydrophobic (SH) protein, glycoprotein (G), and large (L) polymerase protein
(Figure 1). Together, the N, L, and P proteins form the viral replication complex. Interestingly, the
gene order of hMPV is not only different from that of hRSV, but the virus also lacks the non-structural
proteins NS1 and NS2 [3]. Three transmembrane surface glycoproteins are embedded in the lipid
envelope: F, G, and SH. The G protein is important for the attachment of the virion to the host cell.
The F protein mediates fusion of the viral and host cell membrane. The exact function of the SH
protein remains elusive. The F protein sequence is relatively well-conserved between different hMPV
genotypes compared to G and SH which are more variable [24,32,36,37]. In addition, when grafted into
the genome of recombinant replication competent human parainfluenza viruses that were subsequently
used to infect hamsters, hMPV F, but not G or SH, was shown to be able to induce neutralizing
antibodies [38,39]. In the ribonucleoprotein complex, the viral RNA is entirely coated by the N protein,
resulting in flexible helical nucleocapsids, which are also decorated with the P protein and can recruit
the L and M2-1 proteins. In negative-stranded RNA viruses, the viral nucleocapsid serves to protect
the viral RNA from degradation and as a template for viral replication and transcription [40].
Figure 1. Human metapneumovirus (hMPV) virion structure with viral proteins and their function.
Schematic representation of the hMPV viral particle (A) and viral genome with encoded proteins (B):
nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), matrix-2 proteins (M2-1
and M2-2), small hydrophobic (SH) protein, glycoprotein (G), and large (L) polymerase protein.
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In general, when respiratory viruses break through the mucosal layer that lines the airway
epithelial cells (AECs), dendritic cells (DCs) may already come into play, because dendrites of these
cells can sample particles that are present in the airway lumen. DCs that take up virions, for example,
can process viral proteins into peptides for antigen presentation. Upon DC migration to the regional
draining lymph node, the processed viral antigen can be presented to CD4+ and CD8+ T cells.
The activated effector T cells with a matching T cell receptor subsequently expand and travel to the
lung parenchyma where they can eliminate the infected epithelial cells [41].
This well-established immune response is also crucial for hMPV clearance and antiviral defense,
so when the immune system is compromised, hMPV can persist as has been observed in hematopoietic
stem cell recipients [42,43]. Interestingly, hMPV has developed several mechanisms to circumvent the
immune system (reviewed here and in [44]). hMPV infection induces a rather weak immune memory
response, which helps to explain why recurrent infections during life are common [35,45,46]. Here,
we provide a comprehensive overview of the different cell types involved in the immune response
against hMPV infection and some new insights into the strategies the virus has developed to evade the
host immune response.
1.1. Airway Epithelial Cells (AECs)
The major cell populations that can sense hMPV in an acute infection are AECs [47], alveolar
macrophages (AMϕ) [48], and DCs [49]. hMPV primarily replicates in the epithelial cells located in
the upper (nasopharynx) and lower (lungs) respiratory tract [25,26,50–52]. The infection gives rise to
airway epithelial injury and remodeling [53–55]. AECs are armed with pattern recognition receptors
(PRRs) that can recognize pathogen-associated molecular patterns (PAMPs) such as viral RNA. PAMP
recognition triggers signaling cascades that lead to transcriptional upregulation of cytokines and
chemokines and regulate the inflammatory responses in the infected host [56]. In general, two major
PRR pathways have been described that can recognize different viral products: (i) the RIG-I-like
receptors (RLRs) retinoic-acid inducible gene I (RIG-I) and melanoma differentiation-associated
5 (MDA-5) and (ii) Toll-like receptors (TLRs) including TLR3, TRL4, and TLR7. hMPV infection of
A549 cells, a human alveolar type II like epithelial cell line, induces both RIG-I and MDA-5 gene and
protein expression [57]. In addition, A549 cells secrete a variety of cytokines and chemokines, as well as
type I interferons (IFNs), upon hMPV infection [58]. Interestingly, although hMPV can directly induce
RIG-I expression, type I IFNs enhance the induction [57]. Interestingly, RIG-I-dependent signaling,
but not MDA-5, is necessary to induce an antiviral state in A549 cells and reduce viral replication.
Only inhibition of RIG-I expression significantly reduces activation of interferon regulatory factors
(IRFs), transcription factors, and production of type I IFNs [57]. It is important to note that RIG-I
gene silencing resulted in incomplete abrogation of cellular responses and that other pathways are
also involved. Bao et al. showed that TLR3 expression is induced in AECs upon hMPV infection [59].
However, inhibition of TLR3 expression does not affect hMPV-induced chemokine gene expression in
A549 cells [57]. Triggering of RIG-I and MDA-5 leads to the recruitment of a signaling complex to the
outer membrane of mitochondria and activation of IRFs and subsequent IFN and interferon-stimulated
gene (ISG) expression. Mitochondrial antiviral-signaling protein or MAVS has been identified as
an adaptor protein in this signaling complex [60,61] and plays an important role in hMPV-induced
signaling in airway epithelial cells [57].
IFNs are potent antiviral cytokines which also have important roles in shaping the adaptive
immune response [62]. IFNs can amplify the antiviral response and limit viral replication by inducing
the expression of ISGs. Several in vitro studies have shown that different strains of hMPV induce
the production of IFNs (type I, II, and III) in A549 cells and that this response relies on viral
replication [57–59,63,64]. Schoggins et al. have catalogued several ISGs that might have an inhibitory
effect on different DNA and RNA viruses [65]. The top hits for hMPV inhibition are CD9, HPSE, P2BY6,
and interferon induced transmembrane protein 3 (IFITM3) [65]. Supporting that, McMichael et al.
showed that the expression of IFITM3 inhibits hMPV infection in vitro by dysregulation of hMPV F
Viruses 2020, 12, 542 4 of 22
protein-mediated cell to cell fusion [66]. In general, a viral infection induces IFN-dependent antiviral
defense strategies in AECs. As a counteraction, viruses modulate this response via several mechanisms
resulting in inhibition of IFN synthesis, affecting type I IFN responses and blocking the expression of
ISGs [67]. hMPV has been reported to inhibit type I IFN signaling at different levels of the signaling
cascade involving the regulation of signal transducer and activator of transcription 1 (STAT1), STAT2,
Janus kinase 1 (Jak1), tyrosine kinase 2 (Tyk2), and surface expression of interferon alpha receptor
subunit 1 (IFNAR1) [68,69]. In addition, the G protein has been reported to interact with RIG-I and to
block RIG-I-dependent gene transcription and thus IFN production [70]. For a detailed overview of the
interferon response upon hMPV infection in vitro, animal models and clinical settings, we refer to [71].
Triggering of PRRs does not only induce IFN expression, it also upregulates several
pro-inflammatory genes activating the immune response, resulting in pulmonary inflammation and viral
clearance. Chemokines are important cytokines that regulate the migration and activation of leukocytes
including neutrophil, macrophages, and monocytes to the site of infection [72]. hMPV-infected
AECs secrete an important array of pro-inflammatory chemokines carrying CC and CXC motifs [59].
CC-bearing chemokines include CCL2, CCL3, CCL4, and CCL5. CXC-bearing chemokines include
CXCL1, CXCL2, CXCL3, CXCL8/IL-8, CXCL10, and CXCL11. CCL2 is an important chemoattractant
for monocytes [73] whereas CCL3 and CCL4 recruit and activate neutrophils [74]. In a mouse model
of hMPV infection, the majority of lung inflammatory cells are neutrophils and mononuclear cells
including macrophages/monocytes during the first days of infection. However, in cotton rats, recruited
monocyte/macrophage cell counts were lower [75]. In conclusion, the recruitment of monocytes to the
lungs after hMPV infection has been described in hMPV infection animal models, but their importance
has not been fully explored.
hMPV also induces expression of thymic stromal lymphopoietin (TSLP) and interleukin 33 (IL-33)
in AECs in vitro [76]. Both cytokines activate DCs by inducing the expression of OX40L. TSLP-induced
OX40L on DCs primes naïve CD4+ T cells to differentiate into Th2 cells [35,36]. TLSP-activated DCs
in turn produce CCL17, an important Th2 enhancing chemokine and attractor of natural killer (NK)
cells [77,78]. In lungs of hMPV-infected mice, the expression of TSLP and CCL17 was confirmed.
Further studies based on genetic abrogation and immunological blocking of the TSLP-TSLPR pathway
revealed that TSLP is one of the main causes of hMPV-induced lung inflammation, and, remarkably,
also contributed to hMPV replication in mice [76]. More recently, Li et al. showed that only the
pro-inflammatory long form of TSLP (lfTSLP) is induced by hMPV and that the levels of the short form
(sfTSLP) with anti-inflammatory functions are not changed [79]. The lfTSLP induction depends on
the activation of NF-κB downstream of RIG-I and TLR3 and is facilitated by TANK binding kinase 1
(TBK1) [79]. In conclusion, by activating the TSLP pathway and creating a microenvironment that
favors Th2 responses, hMPV might hamper or delay a more efficient antiviral Th1 response [76].
One may expect that viral infection of AECs will result in a gene expression profile with an innate
immune signature. Indeed, several transcriptomic studies focused on the many upregulated genes
that are involved in the initiation of pro-inflammatory and antiviral immune responses, including
chemokines, cytokines, type I IFN, and interferon-inducible proteins [59,64,80]. However, other and
more recent transcriptomic studies also show that metabolic genes and several mucins are upregulated,
and cilium-associated genes are downregulated [63,81]. It is important to note that approximately 20%
of the genes affected by hMPV infection are related to metabolic pathways. Moreover, most of the
core metabolic enzymes are downregulated upon infection [82]. More specifically, hMPV infection
causes tricarboxylic acid (TCA) cycle impairment and drives de novo fatty acid synthesis which has
been shown to be necessary for replication of several viruses [83]. Another interesting observation was
the fact that hMPV induced a progressive decrease of antioxidant enzyme (AOE) expression levels in
AECs and the lungs of infected mice. Reduced AOE expression usually results in increased levels of
oxidative stress markers illustrating an imbalance between reactive oxygen species production and
antioxidant cellular defenses [59,84]. The transcription factor NF-E2-related factor or Nrf2 regulates
antioxidant and cellular protective gene expression, mainly in response to oxidative stress [85]. A recent
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study suggests that NrF2-dependent genes affect viral replication, airway obstruction, clinical disease,
and neutrophilia upon hMPV infection. Using Nrf2 KO mice, Ivancuic et al. showed that functional
deficits in Nrf2 and inadequate AOE expression lead to viral-mediated oxidative stress and damage of
the airways [86].
To limit viral replication and spreading, AECs may undergo programmed cell death or apoptosis
to facilitate viral clearance [87,88]. Marsico et al. monitored the behavior of AECs during acute hMPV
infection (based on the protocol of Bao et al. [58]) using A549 cells and showed massive cell death
characterized by apoptotic nuclei and DNA fragmentation during the first three days and up to seven
days post infection (dpi). Moreover, the caspase-3 and -7 activity gradually increased up to 7 dpi, and
a role for phosphorylation of the Wee1 kinase in the hMPV-driven apoptosis could be identified [89].
Interestingly, the caspase activity decreased at 14 dpi, and the residual epithelial cells at that time point
seem to reverse the apoptotic process. It has indeed been described that prevention of apoptosis in
virus-infected cells represents a critical step in establishing viral persistence. Therefore, a persistent
virus has developed mechanisms to suppress apoptosis for a longer time to maintain a compartment of
infected cells [90]. It is important to note that hMPV persistence has only been described in some mouse
studies [54,91–93] and a few immunocompromised patients of which some had no symptoms [42,43,94].
Additionally, hMPV persistence has been described in vitro in A549 cells by Marsico et al. [89]. This
study showed that at 14 dpi, the hMPV-infected cells were still metabolically active which could
represent the beginning of coexistence between AECs and hMPV and thus transition from acute to
persistent infections. In general, viruses may be able to persist by interfering with the induction of
apoptosis. Supporting that, chronic hMPV infection in AECs increased expression of the anti-apoptotic
Bcl-2 protein, which overthrows the apoptotic program [89].
1.2. Alveolar Macrophages (AMϕ)
The resident macrophages of the lungs or alveolar macrophages (AMϕ) are localized in the
airspaces within alveoli. From this unique position AMϕ are able to respond quickly to insults in the
lower airways. Under homeostatic conditions, the AMϕ are kept in a suppressive state by the lung
environment in order to prevent inappropriate inflammatory responses to harmless antigens. However,
upon viral infection, the expression of the negative regulators declines rapidly and the lung environment
is reshaped. Coupled with the detection of viral antigens and exposure to pro-inflammatory mediators,
AMϕ adopt a pro-inflammatory phenotype and initiate the innate immune response and viral
clearance [95]. AMϕ are the primary source of inflammatory and immunomodulatory cytokines in
the lungs. They play a pivotal role against both viral and bacterial pathogens and their depletion
severely impairs the host response [96,97]. AMϕ are the major cellular source of hMPV-induced
type I IFNs IFN-α and -β but also other pro-inflammatory cytokines such as tumor necrosis factor
alpha (TNF-α) and IL-6 in the lungs. Depletion of AMϕ by clodronate-loaded liposomes (L-CL2MBP)
before hMPV inoculation enhanced viral replication, pulmonary inflammation, and airway disease [48].
Interestingly, treatment with L-CL2MBP after hMPV infection did not alter lung viral replication
(Table 1). The results of these depletion studies imply that AMϕ are critical in the early phase of viral
entry and that the virus directly targets AMϕ. This hypothesis was supported by the fact that hMPV
is able to replicate in AMϕ isolated from bronchoalveolar lavage (BAL) fluid, ex vivo, although the
infection is less efficient than in AECs [48]. A recent study by Li et al. shows that infection with hMPV
downregulates C/EBPα, a transcription factor critical for the expression of the homeostatic effector
molecule cyclic adenosine monophosphate or cAMP. The suppressive effect on cAMP could be one of
the events in AMϕ reprogramming in response to hMPV infection [98].
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Table 1. Studies showing the importance of different cell types involved in hMPV infection.
Cell Type Strategy for Cell Type Depletion Time of Depletion Lung Viral Load Lung Inflammationand Histopathology Mouse Strain Reference
Innate
Immunity
AMϕ L-CL2MBP liposomes Before hMPV inoculation Decreased Decreased BALB/c [48]
After hMPV inoculation Unchanged Not investigated BALB/c [48]








Anti CD49b/Pan NK cell antibody Before hMPV inoculation Increased Not investigated BALB/c [91]
Anti NK1.1 antibody Before hMPV inoculation Unchanged Unchanged C57BL/6 [100]




Anti CD4 and anti CD8 antibody Before hMPV inoculation Increased Decreased BALB/c [101]
Anti CD3ε + anti αβTCR antibody Before hMPV inoculation Increased Not investigated BALB/c [91]
CD4+ T Cells Anti CD4 antibody Before hMPV inoculation Unchanged Decreased BALB/c [101]
Tregs FoxP3
DTR mice
Throughout hMPV infection Increased Increased C57BL/6 [102]
Before hMPV inoculation (early) Increased Increased C57BL/6 [102]
After hMPV inoculation (late) Unchanged Increased C57BL/6 [102]
Anti CD25 antibody Before hMPV inoculation Decreased Not investigated C57BL/6 [102]
CD8+ T Cells Anti CD8 antibody Before hMPV inoculation Unchanged Decreased BALB/c [101]
Adoptive transfer hMPV specific
CTLs in Rag1−/− mice Before hMPV inoculation Decreased Not investigated BALB/c [103]
γδ T Cells TCR-δ KO mice(B6.129P2-Tcrdtm1Mom/J) Before hMPV inoculation Not investigated Decreased C57BL/6 [99]
hMPV = human metapneumovirus; AMϕ = alveolar macrophages; NK = natural killers cells; NKT = natural killer T; CTL = cytotoxic T lymphocytes; Tregs = regulatory T cells; TCR = T
cell receptor; CD = cluster of differentiation; KO = knockout; Rag = recombination activating gene; Ly6G = lymphocyte antigen 6 complex, locus G.
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1.3. Neutrophils
One of the first type of cells to arrive at the site of respiratory virus infections are neutrophils
that specialize in the elimination of infected cells and clearance of microbial pathogens, dead cells,
and debris [95]. In addition to their cytotoxic function, they also play a critical role in the innate
and adaptive immune response by initiating crosstalk between resident and recruited immune cells
including DCs and T cells. The secretion of cytokines and chemokines but also MHC molecules
initiates this pivotal crosstalk [104]. It is important to note that, in general, respiratory viruses are
not able to infect neutrophils productively. However, these cells can possibly phagocytose virions
and apoptotic bodies that contain virus-derived gene products but this has not been described for
hMPV [105]. Generally, neutrophils migrate to the site of infection at early time points and their potent
but non-specific cytotoxic activity is short-lived. It is important that sufficient neutrophils are recruited
in order to control virus dissemination but an excessive neutrophil response can be detrimental for the
host. Therefore, neutrophils undergo apoptosis, and the apoptotic bodies and debris they leave behind
are cleared by macrophages [95].
The fast influx of neutrophils upon hMPV infection has been well documented in animal studies.
In mouse BAL fluid, a significant neutrophilia was observed within the first three days of infection.
Moreover, neutrophil counts peaked on day one to two post-infection but decreased gradually starting
on day four until day seven (reviewed by Cheemarla et al. [106]). Similar to what is seen in animal
studies, hMPV infection is associated with neutrophil influxes in the airways of infected infants.
Moreover, high cytotoxic neutrophil infiltration and high amounts of their degranulation products
were strongly associated with an increased airway tissue injury [107]. The high neutrophil numbers
positively correlated with the high expression levels of chemokines including KC (in mice [75]) and
IL-8 (in infants [20]). Interestingly, in a first study where depletion of neutrophils was achieved by an
anti-mouse Ly6G-specific monoclonal antibody [108], both inflammation and, surprisingly, lung viral
loads were significantly reduced (Table 1) [76]. These results suggest that the recruitment of neutrophils
in the airways supports viral replication albeit via an unknown mechanism. In contrast, a more recent
study, with the same monoclonal antibody, showed an increased pulmonary inflammation and more
severe clinical disease in neutrophil-depleted mice [99]. In this study, neutrophils did not contribute to
lung viral clearance since no difference was observed in lung viral titers in the presence or absence
of neutrophils (Table 1) [76]. The different outcomes of the two mouse studies can be explained by
the difference in the administration scheme of the anti Ly6G antibody or the different hMPV strains
used for infection. It is also important to note that during severe lung inflammation, a heterogeneous
neutrophil population with distinct activation profiles and different effects on T cells characterize the
systemic and local responses [109]. Therefore, one subset of mature neutrophils can clear infection and
activate the immune system whereas others induce immunosuppression [110,111].
During hMPV infection, the G protein contributes to the recruitment of neutrophils. The exact
mechanism still needs to be unraveled but potentially involves the inhibition of IFN responses by
the G protein [112]. The G protein has an inhibitory effect on RIG-I mediated activation of IFN-α
and IFN-β production [69,70] and inhibits the production and activation of IFN-λ [113]. Inhibition of
IFN signaling would lead to higher levels of chemokines and higher neutrophil numbers in the lung.
Indeed, infection with recombinant hMPV that lacks the G gene is associated with a reduced expression
of TNF-α and IL-17, both known to promote expression of neutrophil chemotactic cytokines [112].
Although it is not known if other hMPV proteins have an effect on neutrophil function, it is likely that
proteins that interfere with the IFN pathway such as the SH and M2-2 proteins will have an impact on
neutrophil recruitment.
1.4. Dendritic Cells (DCs)
Respiratory tract DCs are present within the airway epithelium, submucosa, and lung parenchymal
tissue under normal, resting conditions. They are highly likely to encounter virions because of their
strategic location at the site of virus entry where they can sample antigens throughout the upper and
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lower respiratory tracts [114]. Upon infection, DCs can be activated directly by the virus through
PRRs or indirectly by pro-inflammatory chemokines and cytokines released by AECs or other resident
immune cells [115]. Activated DCs can migrate to the draining lymph nodes where they activate
the adaptive immune response or they can stay in the lungs and promote immune responses locally.
Plasmacytoid DCs (pDCs) play an essential role in the initial sensing of viral pathogens and initiation
of immune response predominantly via the production of type I IFNs. Conventional DCs (cDCs) are
mostly associated with the lung epithelium and migrate to the draining lymph nodes in the first days
after infection where they function as antigen presenting cells (APCs) [95].
The initiation of the immune response via the secretion of IFNs, chemokines, and other cytokines
but also the upregulation of a variety of costimulatory molecules and receptors or cell maturation
is crucial for priming virus-specific CD4+ T cells and to initiate the antiviral response. Two groups
have shown that hMPV can infect both cDCs and pDCs [49,114,116,117]. Although hMPV infection of
DCs results in the expression of viral proteins, no major cytopathic effects such as syncytia formation
or massive apoptosis were observed [49]. In addition, hMPV infection in both DC subtypes failed
to induce a limited production of IFN-α [117]. Both TLR7 and MyD88 are essential for the secretion
of type I IFNs by hMPV-infected pDCs [118,119]. Importantly, hMPV infection in DCs also induces
the expression of several microRNAs (miRs) such as hsa-miR-182-5p and hsa-miR-4634. Although
several microRNAs are believed to be known regulators of DC functions, including maturation, antigen
presentation, and cytokine production, no link between the target genes of the hMPV-induced miRNAs
and DC function has been found [120,121].
Despite the fact that hMPV-infected DCs showed a mild upregulation of co-stimulatory molecules
on their surface, they fail to activate specific naïve T cells efficiently [114,122,123]. Priming of
hMPV-specific CD4+ T cells by DCs is a critical process in the induction of an antiviral response
so naturally, hMPV seems to have developed several mechanisms to impair these functions of
DCs [116,123].
To maintain efficient virus growth, hMPV has developed different strategies to minimize host
IFN production. It is important to note that some of the studies described gave conflicting results,
and there is still no consensus about the interactions between hMPV proteins and different host factors
associated with the immune response. When investigating activation of IFN pathways upon hMPV
infection, it is important to keep in mind that in vitro passage of hMPV may lead to the accumulation
of so-called defective interfering (DI) particles [124]. DIs arise spontaneously when virus are passaged
at high multiplicity of infection (m.o.i). in mammalian cell lines due to errors made by the replicase
complex and consist of virions with partially deleted viral genomes [125]. Therefore, the presence of
DIs could possibly explain the discrepancy in the reported results concerning IFN induction.
The G and SH proteins have been considered for a long time as non-essential proteins for hMPV
replication, illustrated by the observation that recombinant hMPV viruses lacking either G, SH or both
genes can replicate efficiently in vitro and in vivo [80,126–128]. However, Le Nouën et al. showed that
DCs infected with hMPV mutants that lack both the SH and G genes had an increased maturation
rate and were able to prime naïve T cells [122]. In addition, Kolli et al. suggested that G promotes
the inhibition of TLR4 signaling in DCs, which affects type I IFN secretion [129]. The G protein has
also been reported as an interferon antagonist in AECs by Bao et al. [70]. Unfortunately, using siRNA
against the G gene, Preston et al. were unable to confirm these results [130], so the question if the G
protein interferes with the IFN response remains unanswered for AECs. One group showed that hMPV
uses the SH protein to interfere with the TLR7/MyD88 pathway, resulting in the inhibition of type I IFN
induction in pDCs [118,131]. Supporting an inhibitory role for SH, Hastings et al. showed that transient
expression of the hMPV SH protein was able to prevent IFN-induced STAT1 phosphorylation in Vero
cells. Additionally, infection with a recombinant hMPV strain lacking SH resulted in phosphorylation
of STAT1 at the same level as uninfected cells [132]. In contrast, de Graaf et al. were unable to
identify any function of SH in the context of viral replication or immune response in vitro in the
host cell using an hMPV mutant lacking SH [80]. In addition, infection with recombinant hMPV
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that lacks SH presented no difference in viral kinetics and pathogenesis in a rodent model [126] and
minimal attenuation in non-human primates [133]. In addition to the well-studied G and SH proteins,
other viral proteins have been described to mediate hMPV immune evasion. A study by Ren et al.
indicated that DCs infected with an hMPV mutant lacking the M2-2 protein produce higher amounts
of MyD88-dependent genes including cytokines, chemokines and type I IFNs [134]. More specifically,
M2-2 blocks the TLR7/9 dependent signaling pathway by suppressing IRF7 homodimerization through
partial inhibition of IRF7 phosphorylation [135]. Two putative PDZ binding motifs in M2-2 play a
major suppressive role in cellular innate immunity both in vitro and in vivo [136,137]. Infection of
mice with reverse engineered hMPV virus with mutations in the M2-2 PDZ-binding motif induced
higher DC maturation and recruitment of DCs and T cells in the lungs. These in vivo results highlight
the potential for modification of M2-2 PDZ-binding motifs in order to overcome poor mucosal innate
immunity upon hMPV infection [138].
1.5. Natural Killer Cells (NKs)
Natural killer (NK) cells respond to viral infection mainly by killing virus-infected cells but also
by mediating the adaptive immune response. NK cells are perfectly equipped to distinguish normal
cells from virus-infected cells. They express a specialized repertoire of both inhibitory and activating
receptors regulating their activity. A large family of inhibitory receptors is able to recognize self-ligands
such as MHC class I. In contrast, the number of different NK-activating receptors is limited. In humans,
the most important activating NK cell receptors are NKp46, which belongs to the natural cytotoxicity
receptors (NCR), and the NKG2D receptor that interacts with stress-induced ligands such as MICA
and MICB [139,140]. NKp46 is the only NCR member that has a mouse orthologue named Ncr1.
In addition to their direct cytotoxic effect via the release of cytotoxic granules, NK cells also increase
cytotoxic T lymphocyte (CTL) activity via the production of IFN-γ [141].
The role of NK cells in the antiviral response against hMPV infection appears to be mouse strain
dependent. In both BALB/c and C57BL/6 mouse strains, NK cells are recruited to the lungs upon hMPV
infection [91,92,100,142]. Moreover, the recruited NKs are activated, as indicated by the increased
release of cytotoxic granules [100,142]. However, depletion of NK cells in BALB/c mice increases
the lung viral titers [91] but no effect on viral titers has been seen in C57BL/6 mice (Table 1) [100].
It is important to note that NK1.1 antibody treatment depletes not only NK cells but also NKT cells.
NKT cells embody a mixed population of T cells that possess killing properties of both NK and T cells
and form a bridge between the innate and adaptive immune system. During viral infections, NKT cells
exert effector functions but also regulate immune responses in order to limit lung inflammation [41].
Interestingly, a recent study by Gaya et al. showed that NKT cells promote B cell immunity during
viral infections via the release of IL-4 [143]. To exclude the fact that the effects with the NK1.1 antibody
might be due to NKT cell depletion, CD1d-deficient mice [144] were infected with hMPV. These mice
lack NK1.1+ NKT cells but have normal NK cell numbers and have similar viral titers as NK1.1
antibody-treated mice upon hMPV infection (Table 1) [100]. Together, the mouse studies performed by
Wen et al. exclude a role for NK and NKT cells in HMPV infection [100].
Upon hMPV infection, the expression of ligands for the activating receptors NKp46 and NCR1
increased [145]. Surprisingly, hMPV proteins do not appear to be recognized by the activating receptors
and it remains unclear what the ligand of hMPV-infected cells is. As it is the case for other immune cells
of the innate system, hMPV presumably benefits from the avoidance of recognition by NK cells. One
possible mechanism is through downregulation of the stress ligand MICA, one of the major ligands
of the activation receptor NKG2D and via upregulation of MHC class I, a ligand of the inhibitory
receptor [145]. It is also likely that both the G and SH proteins of hMPV inhibit the recruitment of NK
cells as these proteins affect the profile of chemokines produced after infection. 1.6. T cells
Conventional T cells play an important role in the control of hMPV replication in the lung during
both the early and late phase of hMPV infection. When the total T cell population is depleted in mice,
increased viral replication in the lung is observed (Table 1) [91]. In mouse models of hMPV, the number
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of both CD4+ and CD8+ T cells increased on day four and peaked on day six or eight, respectively.
Interestingly, the levels were still elevated two weeks after infection [101]. In hMPV-infected mice,
depletion of CD4+ and CD8+ T cells resulted in significantly higher body weight compared to
control-treated hMPV-infected animals. The effect was most pronounced when CD4+ T cells were
depleted, and no further protection was observed when both cell types were depleted simultaneously
(Table 1) [101]. Surprisingly, depletion of CD4+ T cells or CD8+ T cells alone reduces lung pathology
without affecting the viral load. Depletion of both subsets did result in higher viral titers, showing that
both CD4+ and CD8+ T cells are necessary for clearing the primary infection in the lungs. Together,
these data show that CD4+ or CD8+ T cells play an antiviral role by themselves, but the two subsets
combined are more effective in the eradication of hMPV from the lungs. In order to evade the immune
response, hMPV delays CTL responses [92]. In combination with an abnormal T helper response
induced by hMPV-infected DCs, this results in poor clearance of the virus in the lungs [92].
Over the last years, the interest in the role of non-conventional T cells in immune homeostasis and
during infections has increased. Non-conventional T cells, including γδ T cells, differ from conventional
T cells in many ways and are important in bridging the innate and adaptive arms of the immune system.
Their ability to exert effector functions soon after activation makes them, in contrast to conventional T
cells, important in the early phase of infection. Unfortunately, due to their limited receptor diversity,
they recognize conserved, non-peptide antigens [146]. Interestingly, when neutrophils were depleted
in hMPV-infected mice, no difference in the number of CD4+ T and CD8+ T cells in the lung was
observed; only a significant increase in lung γδ T cells was reported [99]. Under normal conditions,
low numbers of γδ T cells reside in the lung in close proximity to epithelial mucosa. These cells are
ideally located to participate in the first line of defense against infection [90]. After hMPV infection,
the number of these non-conventional T cells increased after five days and the levels remained high
after 15 days. In addition, TCRδ KO mice showed decreased pulmonary inflammation upon hMPV
infection, supporting an immune suppressive role of γδ T cells in the hMPV-induced inflammatory
response (Table 1) [99].
1.5.1. CD4+ T Cells
Early studies in BALB/c mice reported a Th1 response in the first week after hMPV infection,
which controls initial virus replication. At later time points, polarization towards a Th2 immune
response occurs and facilitates viral persistence [91,92]. The observed Th1 phenotype in mice correlates
with the cytolytic activity of peripheral blood mononuclear cell (PBMCs) isolated from adults infected
with hMPV and the predominant Th1 response generated in infected infants [147,148]. More recently,
Douville et al. could not distinguish Th1 responses in the first week of hMPV infection in mice and
concluded that mixed Th1 and Th2 responses mediate the immune reaction [149]. It is now clear
that hMPV induces a complex T cell response, which is not well characterized and might include a
mixed Th1/Th2 response. Independent of their phenotype, CD4+ T cells produce an inefficient IFN-γ
response when activated with hMPV-infected PBMCs in vitro [149]. The observed impairment of T
cell immunity upon hMPV infection is most likely due to impaired functions of hMPV-infected DCs.
Indeed, in vitro studies have shown that the SH and/or G proteins reduce CD4+ T cell proliferation in
an assay where they are co-cultured with hMPV-infected DCs [122].
A specific subset of CD4+ T cells, called regulatory T cells or Tregs, are master regulators of the
immune system and immune homeostasis by engaging multiple mechanisms. Tregs can inhibit effector
cell function and proliferation through the expression of inhibitory cytokines such as transforming
growth factor beta (TGF-β) and IL-10. In addition, Tregs can adjust DC function via interaction of
receptors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death
protein 1 (PD-1) with their ligands [150]. In response to hMPV, Tregs accumulate in the lungs of mice
and are activated [102]. The Tregs responding to hMPV are most likely derived from naïve CD4+ T
cells and do not have a thymic origin based on the low expression of markers to phenotype thymic
Tregs. Interestingly, Rogers et al. demonstrated the importance of timing in the depletion of Tregs in
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the course of hMPV infection [102]. hMPV infection in FoxP3DTR mice depleted of Tregs resulted in
lower peak virus titers due to more effective anti-viral CD8+ T cells responses but was also associated
with increased histopathology. It is important to note that the magnitude of the hMPV-specific CD8+
T cell response was unaltered. In contrast, depletion of Tregs immediately before infection by using
an anti-CD25 antibody led to impaired DC and CD8+ T cell migration and delayed virus clearance
(Table 1) [102]. In addition, absence of Tregs in the priming stage of infection skewed CD4+ T cells
towards a Th2 phenotype. However, it was not studied in detail what the implications on virus-specific
T cells were. Rogers et al. describes an important role for Tregs in priming the immune response.
However, after the immune response has been initiated, Tregs are not essential and can even have
detrimental effects [102]. The effect of hMPV infection on Tregs was also visible in a study with
IL-17 deficient mice which have a defect in IL-17 production, leading to an immune response that is
dominated by FoxP3+ Tregs. hMPV-infected IL-17 KO mice did not have altered lung viral titers or
different lung inflammation scores compared to wild type mice [151]. Interestingly, infected IL-17 KO
mice had an increased percentage of Tregs compared to mock-treated IL-17 KO mice and reduced
percentages of Th1 and Th2 in the BAL fluid. It is important to note that the amount of Tregs between
IL17 KO and WT mice was also different in the absence of hMPV. However, no increase after hMPV
infection was seen in WT mice, suggesting that the imbalance between Tregs and Th17 worsens upon
hMPV infection [151].
1.5.2. CD8+ T cells
Virus-specific CD8+ T cells can selectively eliminate infected cells. Following peak expansion, the
CD8+ T cells numbers shrink and a memory population of virus-specific CD8+ T cells remains in the
lungs [41]. hMPV infection results in the accumulation of hMPV-specific cytotoxic and IFN-γ positive
effector cells in both the airways and lungs seven days post infection. As expected, the presence of CTL
activity correlated with the induction of IFN-γ positive CD8+ T cells. A recent study by Tzannou et al.
showed that hMPV-reactive T cells exist in the peripheral blood of healthy and immune-compromised
subjects, although the levels were low and these specific T cells needed to be expanded first. In addition,
they identified a hierarchy of immunodominance based on a number of donors who responded
positively to hMPV antigens. It is interesting that the F protein was recognized by 97% of the donors
followed by N, M2-1, M, P, L, P, and SH in that particular order of dominance [152].
Despite the fact that CD8+ T cells secrete IFN-γ and kill infected cells in vitro, they fail to clear
viruses in the airways in vivo. Studies by Erickson et al. show that CD8+ T cells become exhausted
and upregulate PD-1 and fail to respond when restimulated with viral antigens [153]. Upon hMPV
infection, PD-1-mediated pulmonary CD8+ T cell impairment occurred rapidly, already by day seven,
and continued for several weeks after viral clearance [153]. Exhausted CD8+ T cells upregulate PD-1
in an antigen-dependent manner, so one way to prevent impairment is CD8+ T cell migration outside
the infected lung to escape antigen-driven TCR signaling. In a re-infection model of hMPV, using µMT
mice that lack B cells, impairment of memory CD8+ T cells was also observed, and the expression
of PD-1 was upregulated. Blockade of PD-1 signaling restored CD8+ T cell function in the lung and
enhanced hMPV control in both primary infection and re-infection [153,154]. The exhausted phenotype
was also observed in IFNAR1 deficient mice but the phenotype was linked to upregulation of another
inhibitory receptor, i.e., Tim3, since the expression of PD-1L is driven by IFN signaling [155].
1.6. B Cells
An important step in the control of viral infections is the production of virus-specific antibodies by
B cells. These antibodies can neutralize, opsonize and inactivate virions or facilitate killing of infected
cells. In order to prevent virus dissemination, the spread of infectious virions to neighboring cells needs
to be controlled. Neutralizing antibodies can block the activity of viral surface proteins and prevent
free virions from invading uninfected cells [95]. hMPV-specific antibodies are produced after the first
infection in childhood and are still detectable after 20 years [3,20–22]. The predominant antibodies are
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directed against the F protein of hMPV. There is an inverse correlation between the levels of anti-hMPV
antibodies and susceptibility to hMPV infection [156]. It is important to note that the hMPV-specific
antibody response cannot effectively clear the virus, and hMPV is able to persist in the lungs, even
in the presence of neutralizing antibodies [91,92]. Therefore, control of hMPV is partly mediated by
cytotoxic T lymphocytes and NK cells [91]. The humoral response following natural infection is not
sufficient to prevent re-infections. The interplay between the humoral and cell-mediated adaptive
response is nicely demonstrated by the fact that production of neutralizing antibodies depends on
CD4+ T cells since antibody levels are undetectable in mice depleted of CD4+ T cells [101].
2. Conclusions
One crucial aspect of the development of vaccines or therapeutics is the knowledge of host
immune responses to hMPV infection and understanding of the immunopathology induced by the
virus. In this review we focused on the different cell types that are involved in the immune response to
hMPV infection and their contribution to hMPV replication and pulmonary inflammation. (Figure 2
and Table 1). Although a plethora of immune cells are involved in the immune response evoked
by hMPV infection, the major cell populations that can sense hMPV in an acute infection are AECs,
AMϕ, and DCs. Because of their unique location, these cells come in first contact, resulting in a first
antiviral response characterized predominately by IFN production. Instantly, hMPV tries to counteract
the response via several immune repressive mechanisms mainly mediated by its surface proteins G
and SH. Since the discovery of hMPV two decades ago, numerous new insights into the interaction
between host and hMPV have been described. Unfortunately, there are several studies with conflicting
results and up to now the roles of the G and SH proteins as antagonists of the immune responses
remain unclear. In the future, it will be necessary to further investigate these interactions in more
detail. In addition to mediators of the innate immune system, T cells, both CD4+ and CD8+ T cells,
play a crucial role in the clearance of hMPV. Not surprisingly, hMPV has also evolved ways to delay
the cytotoxic T cell response and viral clearance by impairing DC cell function. Further, CD8+ T cells
become exhausted and upregulate PD-1 and fail to respond when restimulated with hMPV.
In order to be able to replace symptomatic treatment with hMPV-targeted therapies, further
research is also needed into the replication cycle of hMPV. For example, a recent report shows
that the formation of cytoplasmic inclusion bodies is required for hMPV genome replication and
transcription [157]. Additionally, Pan et al. recently resolved the structure of the polymerase
phosphoprotein complex [158]. These new observations are crucial in understanding hMPV biology
and can lead to the development of new therapeutic strategies. In addition, a vaccine that can prevent
disease caused by hMPV infection is highly desirable. Vaccine development for hMPV is, however,
challenging because the antibody response induced by natural infection wanes over time [156] and the
memory response in the host is weak [149]. Re-infections with hMPV are thus common in both children
and adults. Vaccination strategies that merely aim to induce robust virus-specific neutralizing antibody
responses should therefore aim to induce long-lasting immunity, which may be achievable with certain
adjuvants [159,160]. In addition, the development of a CD8+ T cell-mediated vaccine could be pursued
whether or not in combination with the induction of neutralizing antibodies. In order to include CD8+
T cell responses within a future vaccine strategy, more research is definitely needed, especially into the
balance between cell-mediated protection and immunopathology. Furthermore, T cell impairment
may represent a barrier to vaccination for ARTI, but pharmacologic restoration of T cell function by
using, for example, PD-1 blockers, can have detrimental effects in the lungs as well [161].
The human respiratory system is a playground for hMPV. Ultimately, it may take a combination of
a directly acting antiviral agent and a host response-modulating drug to control severe disease caused
by hMPV.
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Figure 2. Schematic overview of the interplay between different cell types leading to pulmonary
immunopathology upon hMPV infection described in this review. Briefly, dendritic cells (DC), airway
epithelial cells (AECs) and alveolar macrophages (AMϕ) are the major cell populations that sense hMPV
infections. AMϕ initiate the primary innate immune response and viral clearance by phagocytosis of
hMPV virions. Infected AECs release several pro-inflammatory cytokines, chemokines, and interferons
(IFNs) and eventually undergo apoptosis. The signaling pathways induced upon hMPV infection are
presented in the zoomed-in box on the right. Activated DCs can stay in the lung and promote local
immune responses or they can migrate to the draining lymph nodes and prime naïve T cells (Th0).
The activated effector CD4+ and CD8+ T cells expand and migrate back to the lung. Th0 cells can
differentiate into several T cell subsets upon hMPV infection including Th1, Th2, regulatory T cells
(Tregs), NKT cells, and cytotoxic lymphocytes (CTLs). The last two subsets are able to kill infected
cells by the release of cytotoxic granules. Chemokine release by infected AECs recruits several other
inflammatory cell types such as NK cells, monocytes, and neutrophils, mediating viral clearance via
various killing mechanisms. Another important step in the control of viral infection later in the infection
is humoral response through the production of virus-specific antibodies by B cells.
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